AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02413320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT02413320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02413320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT01618097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Decision Aid
Description: Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
Study NCT01618097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Based Decision Aid
Description: Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
Study NCT01299363 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dilator use
Description: Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
Study NCT02212847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular stimulation
Study NCT00891735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Sterile solution for intravitreal injection.
Study NCT04345419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir as antiviral drug
Study NCT04345419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Standard of care treatment
Study NCT04345419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care treatment
Description: Standard of care treatment
Study NCT02183714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songha Night ®
Study NCT02183714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01486862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
Study NCT01995929 — intervention group
Intervention type: PROCEDURE
Intervention: transnasal functional endoscopy
Study NCT02964156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supersole
Description: A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
Study NCT02964156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention
Study NCT03807531 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Temporary Spur Stent System
Description: Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
Study NCT01454804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
Study NCT01454804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Starting dose 500 mg by mouth every day for 28 days.
Study NCT01454804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin®)
Description: 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase
Study NCT01454804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose 200 mg by mouth every day for 28 days.
Study NCT03156036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus temozolomide VS Capecitabine
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day
Study NCT03156036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus temozolomide VS Capecitabine
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day
Study NCT00954395 — intervention group
Intervention type: OTHER
Intervention: D-dimer
Description: D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
Study NCT03585790 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with Multifocal Optics
Description: This contact lens has optics to aid the accommodative and convergence systems
Study NCT02506738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention using mHealth
Description: Patients in the intervention used at home a mobile system to monitor their clinical and health status.
Study NCT03585790 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with Single Vision Optics
Description: This contact lens has standard single vision optics
Study NCT03479749 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RegenoGel-OSP, RegenoGel
Description: RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
Study NCT00323882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-010
Description: selected dose administered IV every 3 weeks
Study NCT02682238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000, 15%
Study NCT02682238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study NCT03479749 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RegenoGel-OSP, RegenoGel
Description: RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
Study NCT03846765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period.
Study NCT03846765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period.
Study NCT03212339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention
Description: Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
Study NCT03128723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acne Mask
Description: The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
Study NCT03660384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV/SO
Description: Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
Study NCT03660384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV/C3F8
Description: Subjects receive 16% C3F8 gas tamponade during vitrectomy
Study NCT03106662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10\^8 cell/kg mesenchymal stem cells will be infused.
Study NCT03106662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide administration
Description: After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
Study NCT01975623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONIC ACE®+ Shears (HS)
Description: We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
Study NCT04656223 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: MF/IND/GLY plus sensor system
Description: There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label.
Study NCT04656223 — intervention group
Intervention type: DRUG
Intervention: FDC therapy
Description: There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Study NCT01331187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pocket-size ultrasonography
Description: Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
Study NCT03926143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (Anetumab ravtansine)
Description: BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
Study NCT01331187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No intervention, except for usual care (goal-directed diagnostics)
Study NCT01641068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Participate in memory and thinking skills workshop
Study NCT01641068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Participate in workshops focusing on increasing knowledge and education on the brain and cognition
Study NCT01641068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo functional neuroimaging
Study NCT01641068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo functional neuroimaging
Study NCT01641068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Intervention
Description: Participate in memory and thinking skills workshop
Study NCT01641068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01641068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01641068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01641068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03374462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Intervention
Description: Home-based telemedicine visits
Study NCT02527382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed stump
Description: Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
Study NCT02960594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1400
Study NCT02960594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012
Study NCT02960594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1401
Study NCT02442934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of the IPREA3 questionnaire
Description: On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
Study NCT02442934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of the IPREA3 questionnaire
Description: On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
Study NCT02442934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate feedback through electronic reminder messages
Description: After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
Study NCT02442934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted interventions in each ICU to reduce discomforts
Description: These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures.
Study NCT02989233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video
Study NCT03001063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supported Self-Management
Description: This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
Study NCT03001063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced treatment as usual
Description: Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
Study NCT00035581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: poly I-poly C12U
Description: 200-400 mg IV infusions 2x/week for 24 weeks
Study NCT00854711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: 80 PPM
Study NCT00854711 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: inhaled nitric oxide
Description: 80 PPM
Study NCT00505570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER® PFO Occluder Device
Description: PFO device closure
Study NCT02307981 — intervention group
Intervention type: OTHER
Intervention: Training with vision teacher (visual rehabilitation)
Description: Individually adapted training With vision teacher
Study NCT04012112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thoracolumbar brace (Flexpine brace)
Description: Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
Study NCT02833389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: UTTR1147A matching placebo will be administered SC.
Study NCT02833389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UTTR1147A
Description: UTTR1147A will be administered SC.
Study NCT02468284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Study NCT00184522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflurax
Study NCT00184522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Study NCT01173692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
Study NCT01173692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
Study NCT03565133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinine sham feeding quinine
Description: Oral sham feeding with quinine
Study NCT03565133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastric quinine
Description: A gastric capsule containing quinine
Study NCT03565133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral sham feeding placebo
Description: Oral sham feeding with placebo (tap water)
Study NCT03565133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral sham feeding placebo
Description: Oral sham feeding with placebo (tap water)
Study NCT03565133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gastric placebo
Description: A gastric capsule containing placebo (cellulose)
Study NCT03565133 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastric placebo
Description: A gastric capsule containing placebo (cellulose)
Study NCT01162603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann and Perkins applanation tonometry
Description: IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
Study NCT01162603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldmann and Perkins applanation tonometry
Description: IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
Study NCT01162603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAFLUPROST 0.0015% EYEDROPS
Description: Tafluprost 0.0015% preservative-free ophthalmic solution
Study NCT01162603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LATANOPROST 0.005% EYEDROPS
Description: Latanoprost 0.005% preservative-added ophthalmic solution
Study NCT03707171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.